Microbiology/RMM In-Depth Focus 2025
This in-depth focus features articles on rapid microbiological methods, quality control, and using AI to read agar plates.
List view / Grid view
This in-depth focus features articles on rapid microbiological methods, quality control, and using AI to read agar plates.
From groundbreaking cell and gene therapies to cost-effective drug delivery innovations, Europe is emerging as a hub for life-changing therapies. Explore expert insights and innovative solutions shaping the pharmaceutical industry.
In this Guide to Outsourcing article, Doug Botkin, PhD Scientific Portfolio Specialist from Charles River Laboratories, examines how modern microbial ID tools can enhance contamination control strategies and explores the benefits an outsourcing partner can provide.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
The medicine becomes the first EU-approved oral treatment for adults who have postpartum depression (PPD).
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.
The deal with the US biopharma could help address metabolic dysfunction-associated steatohepatitis, one of the most prevalent comorbidities of obesity.
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
Expanding its collaboration with the US biotech will add novel molecular glue degrader-based medicines to the pharma company’s pipeline.
The ICH Assembly’s decision supports progress in promoting international standards for safety assessment of medicines.
The novel approach could enhance quality testing applications in pharmaceutical manufacturing.
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
Gains access to potential breakthrough atherosclerotic cardiovascular disease biologic therapy pacibekitug.
As an important policy tool, the new editions by the WHO mark a “significant” step in broadening access to new medicines with proven clinical benefits.
The regulator’s new principles aim to ease the pathway to regulatory approval for rare disease drug developers in the US.